Goldman Sachs’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.1M Sell
3,751,212
-593,273
-14% -$2.13M ﹤0.01% 2833
2025
Q4
$14.9M Buy
4,344,485
+4,094,268
+1,636% +$18.3M ﹤0.01% 2672
2025
Q3
$1.26M Buy
250,217
+31,492
+14% +$139K ﹤0.01% 4873
2025
Q2
$750K Buy
218,725
+132,242
+153% +$329K ﹤0.01% 4902
2025
Q1
$193K Sell
86,483
-213,330
-71% -$612K ﹤0.01% 5650
2024
Q4
$878K Buy
299,813
+94,106
+46% +$262K ﹤0.01% 4903
2024
Q3
$535K Buy
205,707
+109,939
+115% +$305K ﹤0.01% 5015
2024
Q2
$283K Sell
95,768
-110,659
-54% -$419K ﹤0.01% 5132
2024
Q1
$935K Sell
206,427
-394,814
-66% -$2.01M ﹤0.01% 4393
2023
Q4
$3.43M Buy
601,241
+341,945
+132% +$1.58M ﹤0.01% 3485
2023
Q3
$1.19M Sell
259,296
-160,981
-38% -$979K ﹤0.01% 4148
2023
Q2
$2.71M Buy
420,277
+68,931
+20% +$470K ﹤0.01% 3634
2023
Q1
$2.65M Sell
351,346
-113,530
-24% -$1.03M ﹤0.01% 3628
2022
Q4
$4.71M Buy
464,876
+63,659
+16% +$735K ﹤0.01% 3219
2022
Q3
$3.97M Buy
401,217
+166,730
+71% +$1.83M ﹤0.01% 3345
2022
Q2
$2.5M Buy
234,487
+121,762
+108% +$1.03M ﹤0.01% 3853
2022
Q1
$1.1M Sell
112,725
-22,724
-17% -$215K ﹤0.01% 4740
2021
Q4
$1.94M Buy
135,449
+116,704
+623% +$1.77M ﹤0.01% 4282
2021
Q3
$376K Sell
18,745
-12,310
-40% -$218K ﹤0.01% 5360
2021
Q2
$683K Buy
31,055
+3,323
+12% +$91.6K ﹤0.01% 5023
2021
Q1
$942K Buy
+27,732
New +$1.1M ﹤0.01% 4664

Other funds holding ABCL